King To Submit Additional Studies On Altace Efficacy In Diabetic Patients
Executive Summary
King Pharmaceuticals plans to submit additional data from two studies in support of an Altace effect on diabetes complications.
You may also be interested in...
Merck Cozaar Nephropathy Label Should Include Cardioprotection Uncertainty
Merck's Cozaar labeling for type 2 diabetic nephropathy should convey questions about cardioprotective effect and caution about substitution for ACE inhibitors, FDA's Cardiovascular & Renal Drugs Advisory Committee suggested at its April 12 meeting
Merck Cozaar Nephropathy Label Should Include Cardioprotection Uncertainty
Merck's Cozaar labeling for type 2 diabetic nephropathy should convey questions about cardioprotective effect and caution about substitution for ACE inhibitors, FDA's Cardiovascular & Renal Drugs Advisory Committee suggested at its April 12 meeting
King Altace Label Highlights Data Supporting Efficacy In Diabetic Patients
Labeling for King Pharmaceutical's ACE inhibitor Altace has been updated to highlight substudy data supporting efficacy in diabetic patients, following FDA approval Oct. 5 for reduction in risk of myocardial infarction, stroke and death from cardiovascular causes.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: